Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Anticancer Effects of the Hsp90 Inhibitor 17-Demethoxy-Reblastatin in Human Breast Cancer MDA-MB-231 Cells

  • Zhao, Qing (Faculty of Pharmacy, Bengbu Medical College) ;
  • Wu, Cheng-Zhu (Faculty of Pharmacy, Bengbu Medical College) ;
  • Lee, Jae Kyoung (Chemical Biology Research Center, KRIBB) ;
  • Zhao, Su-Rong (Faculty of Pharmacy, Bengbu Medical College) ;
  • Li, Hong-Mei (Faculty of Pharmacy, Bengbu Medical College) ;
  • Huo, Qiang (Faculty of Pharmacy, Bengbu Medical College) ;
  • Ma, Tao (Faculty of Pharmacy, Bengbu Medical College) ;
  • Zhang, Jin (Faculty of Pharmacy, Bengbu Medical College) ;
  • Hong, Young-Soo (Chemical Biology Research Center, KRIBB) ;
  • Liu, Hao (Faculty of Pharmacy, Bengbu Medical College)
  • Received : 2013.11.14
  • Accepted : 2014.04.01
  • Published : 2014.07.28
Download PDF
⟨ Previous Next ⟩

Abstract

Triple-negative breast cancer (TNBC) possesses a higher rate of distant recurrence and a poorer prognosis than other breast cancer subtypes. Interestingly, most of the heat shock protein 90 (Hsp90) client proteins are oncoproteins, and some are closely related to unfavorable factors of TNBC patients. 17-Demethoxy-reblastatin (17-DR), a novel non-benzoquinone-type geldanamycin analog, exhibited potent Hsp90 ATPase inhibition activity. In this study, the anticancer effects of 17-DR on TNBC MDA-MB-231 cells were investigated. These results showed that 17-DR inhibited cell proliferation, induced apoptosis, and suppressed cell invasion and migration in the MDA-MB-231 cells. Down-regulation of the key Hsp90-dependent tumor-driving molecules, such as RIP1 and MMP-9, by 17-DR may be related to these effects. Taken together, our results suggest that 17-DR has potential as a therapeutic agent for the treatment of TNBC.

Keywords

References

  1. Amend K, Hicks D, Ambrosone CB. 2006. Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res. 66: 8327- 8330. https://doi.org/10.1158/0008-5472.CAN-06-1927
  2. Baichwal VR, Baeuerle PA. 1997. Activate NF-$\kappa{B}$ or die? Curr. Biol. 7: R94-R96. https://doi.org/10.1016/S0960-9822(06)00046-7
  3. Bryan BB, Schnitt SJ, Collins LC. 2006. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod. Pathol. 19: 617-621. https://doi.org/10.1038/modpathol.3800570
  4. Cheng Q, Chang JT, Geradts J, Neckers LM, Haystead T, Spector NL, et al. 2012. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res. 14: R62. https://doi.org/10.1186/bcr3168
  5. Chiosis G, Vilenchik M, Kim J, Solit D. 2004. Hsp90: the vulnerable chaperone. Drug Discov. Today 9: 881-888. https://doi.org/10.1016/S1359-6446(04)03245-3
  6. Da Silva VC, Ramos CH. 2012. The network interaction of the human cytosolic 90 kDa heat shock protein Hsp90: A target for cancer therapeutics. J. Proteomics 75: 2790-2802. https://doi.org/10.1016/j.jprot.2011.12.028
  7. Groblewska M, Siewko M, Mroczko B, Szmitkowski M. 2012. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem. Cytobiol. 50: 12-19. https://doi.org/10.5603/FHC.2012.0002
  8. Han HZ. 2012. Research in progress of triple negative breast cancer molecular targeted therapy. Chinese Clin. Oncol. 17: 470-474.
  9. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, et al. 2008. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 14: 7940-7946. https://doi.org/10.1158/1078-0432.CCR-08-0221
  10. Hong YS, Lee D, Kim W, Jeong JK, Kim CG, Sohng JK, et al. 2004. Inactivation of the carbamoyltransferase gene refines post-polyketide synthase modification steps in the biosynthesis of the antitumor agent geldanamycin. J. Am. Chem. Soc. 126: 11142-11143. https://doi.org/10.1021/ja047769m
  11. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. 2003. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 69: 5898-5903.
  12. Kim MS, Kwak HJ, Lee JW, Kim HJ, Park MJ, Park JB, et al. 2008. 17-Allylamino-17-demethoxygeldanamycin down-regulates hyaluronic acid-induced glioma invasion by blocking matrix metalloproteinase-9 secretion. Mol. Cancer Res. 6: 1657-1665. https://doi.org/10.1158/1541-7786.MCR-08-0034
  13. Kim W, Lee D, Hong SS, Na Z, Shin JC, Roh SH, et al. 2009. Rational biosynthetic engineering for optimization of geldanamycin analogues. Chembiochem. 10: 1243-1251. https://doi.org/10.1002/cbic.200800763
  14. Kim W, Lee JS, Lee D, Cai XF, Shin JC, Lee K, et al. 2007. Mutasynthesis of geldanamycin by the disruption of a gene producing starter unit: generation of structural diversity at the benzoquinone ring. Chembiochem. 8: 1491-1494. https://doi.org/10.1002/cbic.200700196
  15. Messaoudi S, Peyrat JF, Brion JD, Alami M. 2011. Heat shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010. Expert Opin. Ther. Pat. 21: 1501-1542. https://doi.org/10.1517/13543776.2011.594041
  16. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55-63. https://doi.org/10.1016/0022-1759(83)90303-4
  17. Mosser DD, Morimoto RI. 2004. Molecular chaperones and the stress of oncogenesis. Oncogene 23: 2907-2918. https://doi.org/10.1038/sj.onc.1207529
  18. Sankhala KK, Mita MM, Mita AC, Takimoto CH. 2011. Heat shock proteins: a potential anticancer target. Curr. Drug Targets 12: 2001-2008. https://doi.org/10.2174/138945011798829339
  19. Shin JC, Zhu N, Lee DH, Kim WC, Lee K, Shen YM, et al. 2008. Characterization of tailoring genes involved in the modification of geldanamycin polyketide in Streptomyces hygroscopicus JCM4427. J. Microbiol. Biotechnol. 18: 1101-1108.
  20. Whitesell L, Lindquist SL. 2005. Hsp90 and the chaperoning of cancer. Nat. Rev. Cancer 5: 761-772. https://doi.org/10.1038/nrc1716
  21. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. 1994. Inhibition of heat shock protein 90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 91: 8324-8328. https://doi.org/10.1073/pnas.91.18.8324
  22. Wu CZ, Jang JH, Ahn JS, Hong YS. 2012. New geldanamycin analogs from Streptomyces hygroscopicus. J. Microbiol. Biotechnol. 22: 1478-1481. https://doi.org/10.4014/jmb.1206.06026
  23. Wu CZ, Jang JH, Woo M, Ahn JS, Kim SJ, Hong YS. 2012. Enzymatic glycosylation of nonbenzoquinone geldanamycin analogs via Bacillus UDP-glycosyltransferase. Appl. Environ. Microbiol. 78: 7680-7686. https://doi.org/10.1128/AEM.02004-12
  24. Wrona IE, Gozman A, Taldone T, Chiosis G, Panek JS. 2010. Synthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: potent inhibitors of heat shock protein 90. J. Org. Chem. 75: 2820-2835. https://doi.org/10.1021/jo1000109
  25. Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, et al. 2008. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int. J. Cancer 122: 2050-2056. https://doi.org/10.1002/ijc.23337
  26. Xing H, Weng D, Chen G, Tao W, Zhu T, Yang X, et al. 2008. Activation of fibronectin/PI3K/Akt leads to chemoresistance to docetaxel by regulating surviving protein expression in ovarian and breast cancer. Cancer Lett. 261: 108-119. https://doi.org/10.1016/j.canlet.2007.11.022
  27. Zhang H, Burrows F. 2004. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med. 82: 488-499.
  28. Zhao S, Ma W, Zhang M, Tang D, Shi Q, Xu S, et al. 2013. High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients. Med. Oncol. 30: 335. https://doi.org/10.1007/s12032-012-0335-4

Cited by

  1. Identifying Differentially Expressed Genes and Screening Small Molecule Drugs for Lapatinib-resistance of Breast Cancer by a Bioinformatics Strategy vol.15, pp.24, 2014, https://doi.org/10.7314/apjcp.2014.15.24.10847
  2. 17-Demethoxy-reblastatin, an Hsp90 inhibitor, induces mitochondria-mediated apoptosis through downregulation of Mcl-1 in human hepatocellular carcinoma cells vol.47, pp.5, 2014, https://doi.org/10.1007/s10863-015-9620-1
  3. Targeting Cell Survival Proteins for Cancer Cell Death vol.9, pp.1, 2014, https://doi.org/10.3390/ph9010011
  4. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells vol.35, pp.1, 2014, https://doi.org/10.1186/s13046-016-0428-6
  5. Targeting cancer cell mitochondria as a therapeutic approach: recent updates vol.9, pp.9, 2014, https://doi.org/10.4155/fmc-2017-0011
  6. Non-Benzoquinone Geldanamycin Analog, WK-88-1, Induces Apoptosis in Human Breast Cancer Cell Lines vol.28, pp.4, 2014, https://doi.org/10.4014/jmb.1710.10063
  7. Reblastatins Inhibit Phenotypic Changes of Monocytes/Macrophages in a Milieu Rich in 27-Hydroxycholesterol vol.20, pp.2, 2014, https://doi.org/10.4110/in.2020.20.e17
  8. Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions vol.64, pp.5, 2014, https://doi.org/10.1021/acs.jmedchem.0c01180